Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Breast 1

Conditions

Meningeal Carcinomatosis 1Glioma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × WP 744 × CNS × Clear all
NCT00527410 2025-05-30

LMD

Biogen

Phase 1 Terminated
9 enrolled
CNS

Meningeal Carcinomatosis

NCT00538343 2025-05-29

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Biogen

Phase 2 Terminated
14 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00526812 2025-05-28

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

Biogen

Phase 1 Completed
54 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡